SEC Form 4 · accession 0000885590-15-000055
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert L. Rosiello
Officer — EVP, Chief Financial Officer
Period of report
Jul 1, 2015
Accepted (ET)
Jul 2, 2015 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F2 | Jul 1, 2015 | A | 204,000 | $0.00 | A | 216,900 | D | |
| Restricted Share UnitsF3,F4 | Jul 1, 2015 | A | 204,000 | $0.00 | A | 420,900 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This number represents the maximum number of performance-based Restricted Share Units ("PSUs") that can be paid out, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). See note (2).
- F2The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $230.82 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on April 1, 2018, 50% on July 1, 2018 and 25% on October 1, 2018 with early vesting possible at higher TSR levels.
- F3This number represents the maximum number of performance-based Restricted Share Units ("PSUs") that can be paid out, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). See note (4).
- F4The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $230.82 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on April 1, 2020, 50% on July 1, 2020 and 25% on October 1, 2020 with early vesting possible at higher TSR levels.